Pediatric classical Hodgkin lymphoma

Over the past century, classical Hodgkin lymphoma (HL) has been transformed from a uniformly fatal disease to one of most curable cancers. Given high cure rate, major focus HL management is reducing use radiation therapy (RT) and chemotherapy agents such as procarbazine doxorubicin minimize long-term toxicities. In both North America Europe, an important philosophy in guide intensity treatment according risk category disease. The main factors used for classification are tumor stage, bulk disease, presence B symptoms. Response factor guiding utilization RT ongoing Children's Oncology Group (COG) European Network Pediatric Lymphoma (EuroNet-PHL) trials. Both trial groups have transitioned reduced volumes that target highest sites using highly conformal techniques, along with standard or intensified regimens improve outcomes higher patients. However, given potential acute toxicities chemotherapy, immunoregulatory drugs being investigated upcoming purpose this review summarize current approaches treating pediatric COG EuroNet-PHL.